X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.fiercepharma.com/pharma/roches-avastin-recalled-pakistan-after-patients-using-counterfeit-version-label-lost-their
https://www.fiercepharma.com/pharma/patient-deaths-taint-roches-industry-first-early-stage-liver-cancer-readout-tecentriq
https://www.biopharmadive.com/news/roche-tecentriq-avastin-adjuvant-liver-cancer-phase-3/640755/
https://endpts.com/another-avastin-biosimilar-joins-the-party-as-roches-grip-on-the-market-loosens/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125085
https://www.pharmaceutical-technology.com/news/celltrion-vegzelma-ec-approval/
https://endpts.com/microcaps-effort-to-take-on-eylea-with-avastin-biosimilar-faces-significant-fda-roadblock/
http://www.koreabiomed.com/news/articleView.html?idxno=13728
https://www.reuters.com/business/healthcare-pharmaceuticals/fresenius-agrees-two-acquisition-deals-bolster-kabi-drugs-unit-2022-03-31/
https://endpts.com/only-a-pawn-in-their-game-orphan-drug-tax-credit-on-the-chopping-block-again-under-dem-spending-bill/
https://www.fiercepharma.com/pharma/sandoz-spinoff-finally-here-novartis-gets-ball-rolling-strategic-review
https://www.medtechdive.com/news/fda-ends-summer-with-fresh-batch-of-breakthrough-device-designations/606355/
https://www.prnewswire.com/news-releases/therapeutic-solutions-international-files-investigational-new-drug-application-with-fda-for-cancer-blood-vessel-targeting-immunotherapy-stemvacs-v-to-treat-metastatic-breast-cancer-301365037.html
https://www.centerforbiosimilars.com/view/uhc-changes-its-bevacizumab-policy-following-aao-complaint
https://www.fiercepharma.com/pharma/j-j-amgen-and-roche-face-growing-competition-from-biosimilars-are-driving-down-prices-report
https://www.ono-pharma.com/sites/default/files/en/news/press/enews20210621.pdf
https://www.fiercepharma.com/pharma/astrazeneca-takes-parp-battle-to-court-suing-for-more-zejula-shares-key-gsk-s-oncology-pivot
https://www.fiercepharma.com/pharma/astrazeneca-takes-parp-battle-to-court-suing-for-more-zejula-shares-key-gsk-s-oncology-pivot
https://economictimes.indiatimes.com/markets/stocks/news/biocon-tanks-4-as-usfda-defers-decision-on-avastin-biosimilar-application/articleshow/79985981.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://economictimes.indiatimes.com/markets/stocks/news/biocon-tanks-4-as-usfda-defers-decision-on-avastin-biosimilar-application/articleshow/79985981.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://economictimes.indiatimes.com/industry/healthcare/biotech/usfda-informs-biocon-biologics-mylan-of-deferred-action-on-avastin-biosimilar-license-application/articleshow/79953132.cms
https://www.bigmoleculewatch.com/2020/07/07/breaking-news-genentech-and-amgen-settle-herceptin-and-avastin-biosimilar-disputes/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+GoodwinProcter-BigMoleculeWatchBlog+%28Big+Molecule+Watch+Blog+%7C+Goodwin%29
https://www.bigmoleculewatch.com/2020/06/29/new-bpcia-complaint-genentech-seeks-to-block-samsung-bioepiss-proposed-avastin-biosimilar/
https://www.raps.org/news-and-articles/news-articles/2020/6/recon-nih-may-own-ip-for-moderna-covid-19-vaccine
https://www.fiercepharma.com/pharma/asco-merck-s-keytruda-doubles-time-to-disease-progression-certain-colorectal-cancer-patients
https://news.cision.com/astrazeneca/r/lynparza-gets-broader-us-ovarian-cancer-approval,c3108407
https://www.fiercepharma.com/pharma/astrazeneca-merck-s-lynparza-wins-bid-to-challenge-gsk-s-zejula-wider-ovarian-cancer-pool
https://www.biopharmadive.com/news/pfizer-hits-its-biosimilar-stride/571136/
https://www.globenewswire.com/news-release/2020/01/13/1969611/0/en/Coherus-Acquires-Commercial-Rights-for-Avastin-Biosimilar-in-the-United-States.html
https://endpts.com/immunogen-maps-new-path-to-accelerated-approval-biontech-scores-e50m-funding-from-european-bank/
https://www.fiercepharma.com/marketing/roche-aims-for-bayer-s-liver-cancer-share-tecentriq-avastin-survival-win
https://www.biospace.com/article/releases/fda-accepts-samsung-bioepis-bla-for-sb8-bevacizumab-biosimilar-candidate-/?s=95
https://www.biopharmadive.com/news/teva-5-updates-third-quarter-earnings-debt-cash-flow-ajovy-copaxone/566836/
https://bioprocessintl.com/bioprocess-insider/therapeutic-class/pfizer-unveils-biosimilar-launch-plans-and-shares-view-on-us-market/
https://www.fiercepharma.com/pharma/say-hello-to-roche-s-worst-case-scenario-teva-s-rituxan-biosim-set-to-launch-u-s
https://www.fiercepharma.com/pharma/u-s-biosimilars-only-scratched-roche-s-cancer-blockbusters
https://www.centerforbiosimilars.com/news/as-biosimilars-emerge-in-oncology-and-rare-disease-innovator-companies-look-to-new-drugs-to-maintain-sales
https://endpts.com/fda-requests-additional-time-for-flexions-snda-genentech-releases-data-for-phiii-study-of-rituxan/
https://www.fiercepharma.com/pharma/icer-lambasts-abbvie-s-humira-genentech-s-rituxan-and-more-for-unsupported-price-hikes
https://www.biopharmadive.com/news/parp-inhibitor-esmo-astrazeneca-gsk-abbvie/563803/
https://seekingalpha.com/news/3502404-fda-oks-roches-rituxan-rare-blood-vessel-inflammation-diseases
https://www.fiercepharma.com/pharma/biosimilars-will-leave-a-10b-gap-roche-s-sales-but-new-drugs-can-more-than-fill-it-exec
https://www.fiercepharma.com/pharma/biosimilars-will-leave-a-10b-gap-roche-s-sales-but-new-drugs-can-more-than-fill-it-exec
Market Place
Share 
